NCT02997228: An ongoing trial by National Cancer Institute (NCI)
This trial is ongoing. It must report results 2 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02997228 |
|---|---|
| Title | Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 19, 2018 |
| Completion date | June 1, 2027 |
| Required reporting date | May 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |